ArticleEJHaem2025

Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd).

Benjamin J Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.